Russell Investments Group Ltd. Has $7.32 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Russell Investments Group Ltd. increased its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 79.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 247,325 shares of the medical device company's stock after buying an additional 109,505 shares during the quarter. Russell Investments Group Ltd. owned about 0.38% of Tandem Diabetes Care worth $7,316,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in TNDM. RiverPark Advisors LLC purchased a new stake in shares of Tandem Diabetes Care in the fourth quarter worth about $27,000. Signaturefd LLC lifted its stake in shares of Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock valued at $50,000 after purchasing an additional 1,517 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Tandem Diabetes Care by 51.7% during the third quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company's stock worth $67,000 after buying an additional 1,099 shares in the last quarter. GAMMA Investing LLC acquired a new stake in Tandem Diabetes Care during the fourth quarter valued at $73,000. Finally, Creative Financial Designs Inc. ADV purchased a new position in Tandem Diabetes Care in the fourth quarter valued at $104,000.

Tandem Diabetes Care Trading Down 4.2 %

NASDAQ TNDM traded down $1.85 on Wednesday, reaching $42.15. 1,771,921 shares of the company were exchanged, compared to its average volume of 1,767,383. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $47.00. The stock has a market capitalization of $2.72 billion, a P/E ratio of -20.28 and a beta of 1.10. The business's fifty day moving average price is $32.91 and its 200 day moving average price is $26.53. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. The firm had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Analysts forecast that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current year.

Analyst Ratings Changes

TNDM has been the topic of several research analyst reports. StockNews.com raised Tandem Diabetes Care from a "sell" rating to a "hold" rating in a report on Friday, April 19th. Citigroup lifted their price target on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research note on Wednesday, April 3rd. Wells Fargo & Company raised shares of Tandem Diabetes Care from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $21.00 to $45.00 in a report on Monday, April 29th. Leerink Partnrs raised shares of Tandem Diabetes Care from a "market perform" rating to an "outperform" rating in a research note on Thursday, April 25th. Finally, Barclays raised their price target on shares of Tandem Diabetes Care from $39.00 to $55.00 and gave the company an "overweight" rating in a research note on Monday. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of "Moderate Buy" and a consensus price target of $43.80.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.